Last reviewed · How we verify
NCT05644691
Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis
trial testing Lipikar Baume AP+M in Atopic Dermatitis in 119 participants. Completed in 14 July 2021.
14 July 2021
Quick facts
| Lead sponsor | Cosmetique Active International |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 119 |
| Start date | 14 October 2020 |
| Primary completion | 14 July 2021 |
| Estimated completion | 14 July 2021 |
| Sites | 1 location across Slovakia |
Drugs / interventions tested
- Lipikar Baume AP+M
- Usual emollient
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Cosmetique Active International — full company profile →
Who can join
3 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from atopic dermatitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05644691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lipikar Baume AP+M
Trials testing the same drug.
- NCT06385340 — Investigation of the Effect of Lipikar Baume AP+M · NA · recruiting
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Cosmetique Active International trials
Trials by the same sponsor.
- NCT07239726 — CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPI · NA · not yet recruiting
- NCT06590779 — Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss · NA · not yet recruiting
- NCT06516224 — Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma · NA · not yet recruiting
- NCT07537595 — Efficacy of Cosmetic Products in Preventing Pigmentation Induced by High Energy Visible Light (HEVL) [400-450nm] · completed
- NCT06320314 — Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05644691 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cosmetique Active International
- Last refreshed: 9 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05644691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing